AMAG Pharmaceuticals, Inc. to Host Conference Call on March 7, 2012 at 4:30 p.m. ET to Discuss Feraheme Clinical Trial Results

LEXINGTON, Mass.--(BUSINESS WIRE)--Mar 6, 2012 - AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will report preliminary results from the first of two phase III clinical trials of Feraheme for the treatment of iron deficiency anemia regardless of the underlying cause after the U.S. financial markets close on Wednesday, March 7, 2012. The announcement will be followed by a conference call and webcast at 4:30 p.m. ET during which management will discuss the company's results of this study.

To access the conference call via telephone, please dial (877) 412-6083 from the United States or (702) 495-1202 for international access. A telephone replay will be available from approximately 8:30 p.m. ET on March 7, 2012 through midnight March 12, 2012. To access a replay of the conference call, dial (855) 859-2056. The pass code for the live call and the replay is 59989211.

The call will be webcast and accessible through the Investors section of the Company's website at www.amagpharma.com. The webcast replay will be available from approximately 8:30 p.m. ET on March 7, 2012 through midnight April 7, 2012.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia. AMAG manufactures and sells Feraheme® (ferumoxytol) Injection for intravenous use. For additional company or product information, please visit www.amagpharma.com or http://feraheme.com.

Feraheme is a registered trademark of AMAG Pharmaceuticals, Inc.

 

Contact: AMAG Pharmaceuticals, Inc.
Amy Sullivan, 617-498-3303

 

 

Posted: March 2012

View comments

Hide
(web1)